Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,012 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Allogeneic hematopoietic stem cell transplantation Clear all
Active, not recruiting Phase 1 Interventional

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

NCT00145626
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Universal Anti-Viral Vaccine for Healthy Elderly Adults

NCT04441047
View directory record Official record
Conditions
Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia, Influenza, Human, ARDS, Human
Interventions
AlloStim
Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Delray Beach, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
No Longer Available No phase listed Expanded access

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00423826
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 21, 2026, 7:38 AM EDT
Not yet recruiting Early Phase 1 Interventional

NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI

NCT07739043
View directory record Official record
Conditions
SCI - Spinal Cord Injury, SCI, Spinal Cord Injury
Interventions
Human allogeneic, culture expanded, UC-MSC
Drug
Lead sponsor
Cell Therapy LLC
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Recruiting Phase 1 Interventional

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

NCT03541889
View directory record Official record
Conditions
Primary Graft Failure
Interventions
FLT imaging and TK1 blood measurements
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

NCT04429191
View directory record Official record
Conditions
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

NCT04171843
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
PBCAR269A, Fludarabine, Cyclophosphamide, Nirogacestat
Genetic · Drug
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 2Phase 3 Interventional

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

NCT01019876
View directory record Official record
Conditions
Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Interventions
Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

NCT00615589
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Fludarabine/Busulfan x 4 days, stem cell transplant
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 21, 2026, 7:38 AM EDT
Completed No phase listed Observational

Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant

NCT02796196
View directory record Official record
Conditions
Cell Transplantation
Interventions
Medical Chart Review, Monitoring Device, Physical Therapy
Other · Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03564821
View directory record Official record
Conditions
IDH1 Mutation Myeloid Neoplasms
Interventions
Ivosidenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

NCT00986804
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

NCT00079625
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Th2/Tc2 Cells
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 7:38 AM EDT
Recruiting Phase 1 Interventional

Trial of Cell Based Therapy for DMD

NCT06692426
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
MyoPAXon, Tacrolimus
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Results available

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

NCT01173016
View directory record Official record
Conditions
Hurler Syndrome
Interventions
Laronidase
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 14 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 21, 2026, 7:38 AM EDT
Active, not recruiting Phase 1 Interventional

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

NCT04288726
View directory record Official record
Conditions
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Interventions
CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia

NCT00001144
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Graft vs Host Disease
Interventions
Modified bone marrow stem cell transplantation
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 21, 2026, 7:38 AM EDT
Active, not recruiting Phase 2 Interventional

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT03674047
View directory record Official record
Conditions
Other Cancer
Interventions
ruxolitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional

A Standardized Nursing Intervention Protocol for HCT Patients

NCT00951626
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Psychosocial Effects of Cancer and Its Treatment, Therapy-related Toxicity
Interventions
exercise intervention, telephone-based intervention, dietary intervention, educational intervention, questionnaire administration, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, assessment of therapy complications, peripheral blood stem cell transplantation, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress

NCT02037568
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
fPER
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

NCT02737306
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease

NCT04791878
View directory record Official record
Conditions
Perianal Fistula Due to Crohn's Disease (Disorder)
Interventions
Mesenchymal stem cells
Drug
Lead sponsor
Anthony Lembo
Other
Eligibility
13 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 21, 2026, 7:38 AM EDT